MBG novel therapeutics series

Join us Mondays at 4:30PM to hear from biotech professionals about novel therapeutics, which revolutionized pharma over the last decade. In this seminar series, industry leaders provide an overview of the development process for various classes of biologics, from fusion proteins to CAR-T cells, mRNA vaccines, siRNA therapeutics, and more.

9/21 Amgen Roger Hart Scientific Director, Process Development Overview of Drug Modalities
9/28 Amgen Cen Xu Scientific Director, Neuroscience The Science Behind Aimovig
10/19 Moderna Andrea Carfi Head of Research, Infectious Disease Development of mRNA Medicines
10/26 Alnylam Eric Green Senior Vice President, TTR Franchise siRNA Therapeutics
11/2 Beam Adam Hartigan Director of Hematology CRISPR Therapies
11/9 Vertex Paul Negulescu Director of San Franscisco Research Site Cystic Fibrosis Combination Therapies
11/16 Novartis Jennifer Brogdon Exec. Director, Head of Cell Therapy Research Cell Therapies
11/23 Synlogic/Ginkgo David Lubkowicz, Christian Ridley Lead Strain Engineer at Synlogic, Program Lead in Organism Engineering at Ginkgo Synthetic Biology Therapies
11/30 Vertex Angela Yen Leader of Cell and Genetic Therapies Group Gene Therapies
TBA Amgen Panelists Various Careers in Biotech

RSVP: https://forms.gle/25upmPB6ZLf9xxJ87

Zoom link: https://tinyurl.com/y6z6a6fb

  • 00

    days

  • 00

    hours

  • 00

    minutes

  • 00

    seconds

Date

Nov 30 2020

Time

4:30 pm

More Info

Read More

Labels

Learn

Location

Virtual
Category
MIT Biotech Group

Organizer

MIT Biotech Group
REGISTER

Recent Comments

    Archives

    Categories

    • No categories